company background image
1066

Shandong Weigao Group Medical PolymerSEHK:1066 Stock Report

Last Price

HK$9.66

Market Cap

HK$43.7b

7D

-7.1%

1Y

-35.0%

Updated

25 Jan, 2022

Data

Company Financials +
1066 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance4/6
Financial Health5/6
Dividends3/6

1066 Stock Overview

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China.

Shandong Weigao Group Medical Polymer Competitors

Johnson & Johnson

NYSE:JNJ

US$441.3b

Medtronic

NYSE:MDT

US$140.1b

Amgen

NasdaqGS:AMGN

US$126.8b

Intuitive Surgical

NasdaqGS:ISRG

US$94.4b

Price History & Performance

Summary of all time highs, changes and price drops for Shandong Weigao Group Medical Polymer
Historical stock prices
Current Share PriceHK$9.66
52 Week HighHK$20.65
52 Week LowHK$9.20
Beta0.57
1 Month Change2.88%
3 Month Change-27.26%
1 Year Change-34.99%
3 Year Change54.31%
5 Year Change89.78%
Change since IPO5,500.00%

Recent News & Updates

Jan 13
Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Dec 17
Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...

Dec 05
Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Oct 18
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

How far off is Shandong Weigao Group Medical Polymer Company Limited ( HKG:1066 ) from its intrinsic value? Using the...

Oct 06
Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?

Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

1066HK Medical EquipmentHK Market
7D-7.1%-4.7%-0.06%
1Y-35.0%-46.0%-15.0%

Return vs Industry: 1066 exceeded the Hong Kong Medical Equipment industry which returned -47.4% over the past year.

Return vs Market: 1066 underperformed the Hong Kong Market which returned -16.2% over the past year.

Price Volatility

Is 1066's price volatile compared to industry and market?
1066 volatility
1066 Average Weekly Movement5.4%
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.7%
10% most volatile stocks in HK Market13.1%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 1066 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 1066's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200010,792Rinan Conghttps://www.weigaogroup.com

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China. The company operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. It offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound healing dressings, wound sutures, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment.

Shandong Weigao Group Medical Polymer Fundamentals Summary

How do Shandong Weigao Group Medical Polymer's earnings and revenue compare to its market cap?
1066 fundamental statistics
Market CapCN¥35.52b
Earnings (TTM)CN¥2.24b
Revenue (TTM)CN¥12.36b

15.8x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1066 income statement (TTM)
RevenueCN¥12.36b
Cost of RevenueCN¥5.28b
Gross ProfitCN¥7.08b
ExpensesCN¥4.84b
EarningsCN¥2.24b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.50
Gross Margin57.27%
Net Profit Margin18.15%
Debt/Equity Ratio21.9%

How did 1066 perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

29%

Payout Ratio

Valuation

Is Shandong Weigao Group Medical Polymer undervalued compared to its fair value and its price relative to the market?

39.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1066 (HK$9.66) is trading below our estimate of fair value (HK$15.94)

Significantly Below Fair Value: 1066 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1066 is good value based on its PE Ratio (15.8x) compared to the Hong Kong Medical Equipment industry average (20.9x).

PE vs Market: 1066 is poor value based on its PE Ratio (15.8x) compared to the Hong Kong market (9.1x).


Price to Earnings Growth Ratio

PEG Ratio: 1066 is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: 1066 is good value based on its PB Ratio (1.9x) compared to the HK Medical Equipment industry average (2.3x).


Future Growth

How is Shandong Weigao Group Medical Polymer forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

16.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1066's forecast earnings growth (16.7% per year) is above the savings rate (1.5%).

Earnings vs Market: 1066's earnings (16.7% per year) are forecast to grow faster than the Hong Kong market (16.4% per year).

High Growth Earnings: 1066's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1066's revenue (15.5% per year) is forecast to grow faster than the Hong Kong market (11.5% per year).

High Growth Revenue: 1066's revenue (15.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1066's Return on Equity is forecast to be low in 3 years time (13.7%).


Past Performance

How has Shandong Weigao Group Medical Polymer performed over the past 5 years?

16.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1066 has high quality earnings.

Growing Profit Margin: 1066's current net profit margins (18.2%) are higher than last year (17.9%).


Past Earnings Growth Analysis

Earnings Trend: 1066's earnings have grown by 16.3% per year over the past 5 years.

Accelerating Growth: 1066's earnings growth over the past year (17.6%) exceeds its 5-year average (16.3% per year).

Earnings vs Industry: 1066 earnings growth over the past year (17.6%) underperformed the Medical Equipment industry 50.4%.


Return on Equity

High ROE: 1066's Return on Equity (11.9%) is considered low.


Financial Health

How is Shandong Weigao Group Medical Polymer's financial position?


Financial Position Analysis

Short Term Liabilities: 1066's short term assets (CN¥16.1B) exceed its short term liabilities (CN¥5.6B).

Long Term Liabilities: 1066's short term assets (CN¥16.1B) exceed its long term liabilities (CN¥4.1B).


Debt to Equity History and Analysis

Debt Level: 1066 has more cash than its total debt.

Reducing Debt: 1066's debt to equity ratio has increased from 9.4% to 21.9% over the past 5 years.

Debt Coverage: 1066's debt is well covered by operating cash flow (67.4%).

Interest Coverage: 1066's interest payments on its debt are well covered by EBIT (414.6x coverage).


Balance Sheet


Dividend

What is Shandong Weigao Group Medical Polymer current dividend yield, its reliability and sustainability?

1.96%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1066's dividend (1.96%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.34%).

High Dividend: 1066's dividend (1.96%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.94%).


Stability and Growth of Payments

Stable Dividend: 1066's dividend payments have been volatile in the past 10 years.

Growing Dividend: 1066's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.1%), 1066's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 1066's dividends in 3 years are forecast to be well covered by earnings (24.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Rinan Cong (40 yo)

0.83

Tenure

Mr. Rinan Cong serves as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 and serves as Executive Director since May 24, 2021. He joined the Company in...


Leadership Team

Experienced Management: 1066's management team is seasoned and experienced (5.5 years average tenure).


Board Members

Experienced Board: 1066's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shandong Weigao Group Medical Polymer Company Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Shandong Weigao Group Medical Polymer Company Limited
  • Ticker: 1066
  • Exchange: SEHK
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: HK$43.686b
  • Shares outstanding: 4.52b
  • Website: https://www.weigaogroup.com

Number of Employees


Location

  • Shandong Weigao Group Medical Polymer Company Limited
  • Torch Hi-Tech Science Park
  • 18 Xingshan Road
  • Weihai
  • Shandong Province
  • 264210
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/25 15:59
End of Day Share Price2022/01/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.